Michael Gale, PhD

Gale Laboratory conducts Singletto research on various methods of generating singlet oxygen to inactivate COVID-19 viral particles. The lab provides us with the uncommon access and ability to test singlet oxygen solutions—codeveloped by Singletto with licensees—to validate products that decontaminate and protect from pathogens, specifically COVID-19.

A professor of Immunology at the University of Washington, Dr. Gale is an immunologist and virologist with expertise in studies of virus/host interactions, innate immunity, and immune signaling of RNA viruses. His research focuses on the molecular mechanisms of innate immune response and immune programming against infection by RNA viruses, including emerging SARS-CoV-2 or flaviviruses, HIV, and influenza viruses. His group also examines the virus/host interactions that impart immune evasion and disease, and leverages this data to build improved vaccines, vaccine adjuvants, and antiviral therapeutics.

Gale Laboratory is active in the local and national response to SARS-CoV-2 infection and COVID-19 disease. The lab is collaborating with the international community to support the global response to control and prevent SARS-CoV-2 infection. Their efforts include conducting antibody testing to determine community exposure frequency to SARS-CoV-2; assessing SARS-CoV-2 infection and virus replication in cultures; and defining the innate immune and inflammatory programs that are triggered and regulated by SARS-CoV-2 infection to impart COVID-19 disease outcome.